References

1. Archie SR, Cucullo L. Harmful Effects of Smoking Cannabis: A Cerebrovascular and Neurological Perspective. Front Pharmacol.2019; 10: 1481-1481. https://doi.org/10.3389/fphar.2019.01481
2. Borgan F, Beck K, Butler E, McCutcheon R, Veronese M, Vernon A, et al. The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. Psychopharmacology. 2019; 236(11): 3257-3270. https://doi.org/10.1007/s00213-019-05283-3
3. Kögel CC, López-Pelayo H, Balcells-Olivero M, Colom J, Gual A. (2018). Psychoactive constituents of cannabis and their clinical implications: a systematic review Constituyentes psicoactivos del cannabis y sus implicaciones clínicas: una revisión sistemática. Adicciones. 2018; 30(2): 140-152. 4.
4. Cohen K, Kapitány-Fövény M, Mama Y, Arieli M, Rosca P, Demetrovics Z, et al. The effects of synthetic cannabinoids on executive function. Psychopharmacology. 2017; 234(7): 1121-1134. https://doi.org/10.1007/s00213-017-4546-4
5. NIDA. (2019). Marijuana as Medicine. Retrieved 2020, May 29 https://www.drugabuse.gov/publications/drugfacts/marijuana-medicine
6. Ribeiro LI, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med. 2016; 26: 16071-16071. https://doi.org/10.1038/npjpcrm.2016.71
7. Koren G, Cohen R. Medicinal Use of Cannabis in Children and Pregnant Women. Rambam Maimonides Med J. 2020; 11(1). https://doi.org/10.5041/RMMJ.10382
8. Wang B, Kovalchuk A, Li D, Ilnytskyy Y, Kovalchuk I, Kovalchuk O. (2020). In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues. Preprints. https://doi.org/10.20944/preprints202004.0315.v1
9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. https://doi.org/10.1016/j.cell.2020.02.052
10. Palmatier RW, Houston MB, Hulland J. (2018). Review articles: Purpose, process, and structure. J Acad. Mark Sci. https://doi.org/10.1007/s11747-017-0563-4
11. Williams K. (2014). The different ways to smoke and consume cannabis Retrieved from https://www.leafly.com/news/cannabis-101/the-complete-list-of-cannabis-delivery-methods
12. Baldwin J. (2020). Healthiest Ways To Consume Weed: Better Than Smoking [Press release]. Retrieved from https://www.weednews.co/healthiest-ways-to-consume-cannabis/
13. Romano L, Hazekamp A. An Overview of Galenic Preparation Methods for Medicinal Cannabis. Curr Bioact Compd. 2019; 15(2): 174-195. https://doi.org/10.2174/1573407214666180612080412
14. NIDA. (2020, June 6). Marijuana DrugFacts. https://www.drugabuse.gov/publications/drugfacts/marijuana
15. Franklin RM, Rosenthal E, Franklin RM. (2019). Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil. Retrieved from https://patents.google.com/patent/US9629886B2/en
16. Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, et al. Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users. J Anal Toxicoly. 2020; 44(1): 1-14. https://doi.org/10.1093/jat/bkz038
17. Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F. Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules. 2018; 23(10): 2478. https://doi.org/10.3390/molecules23102478
18. Holitzki H, Dowsett LE, Spackman E, Noseworthy T, Clement F. Health effects of exposure to second-and third-hand marijuana smoke: a systematic review. CMAJ open. 2017; 5(4): E814. https://doi.org/10.9778/cmajo.20170112
19. International Agency for Research on Cancer. (2019). IARC monographs on the identification of carcinogenic hazards to humansList Classif. Agents Classif. by IARC Monogr (Vol. 1). Lyon, France. Retrieved from https://monographs.iarc.fr/agents-classified-by-the-iarc/.
20. Swenberg JA, Moeller BC, Lu K, Rager JE, Fry RC, Starr TB. Formaldehyde carcinogenicity research: 30 years and counting for mode of action, epidemiology, and cancer risk assessment. Toxicol Pathol. 2013; 41(2): 181-189. https://doi.org/10.1177/0192623312466459
21. Abdel-Shafy HI, Mansour MS. (2016). A review on polycyclic aromatic hydrocarbons: source, environmental impact, effect on human health and remediation. EJP, 25(1): 107-123. https://doi.org/10.1016/j.ejpe.2015.03.011
22. Nakajima D, Yagishita M. (2018). Carcinogenicity/MutagenicityPolycyclic Aromatic Hydrocarbons (pp. 235-244): https://doi.org/10.1007/978-981-10-6775-4_18
23. Dong H, Xian Y, Li H, Bai W, Zeng X. Potential carcinogenic heterocyclic aromatic amines (HAAs) in foodstuffs: Formation, extraction, analytical methods, and mitigation strategies. Comprehensive Compr Rev Food Sci. 2020; 19(2): 365-404. https://doi.org/10.1111/1541-4337.12527
24. Tan SLW, Chadha S, Liu Y, Gabasova E, Perera D, Ahmed K, et al. (2017). A class of environmental and endogenous toxins induces BRCA2 haploinsufficiency and genome instability. Cell, 169(6): 1105-1118. e15. https://doi.org/10.1016/j.cell.2017.05.010
25. NCBI. Isobutylene. Retrieved June 19, 2020, from PubChem Database https://pubchem.ncbi.nlm.nih.gov/compound/Isobutylene
26. Coddington H. (2017). Dabbing, Terpenes, and the Possibility of Carcinogens. https://gopurepressure.com/blogs/rosin-education/dabbing-terpenes-and-the-possibility-of-carcinogens
27. World Health Organization. (2018). Delta-9-tetrahydrocannabinol WHO Expert Committee on Drug Dependence Critical Review. Retrieved from https://www.who.int/medicines/access/controlled-substances/THCv1.pdf?ua=1
28. Russo C, Ferk F, Mišík M, Ropek N, Nersesyan A, Mejri D, et al. Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells. Arch Toxicol. 2019; 93(1): 179-188. https://doi.org/10.1007/s00204-018-2322-9
29. Graves BM, Johnson TJ, Nishida RT, Dias RP, Savareear B, Harynuk JJ, et al. Comprehensive characterization of mainstream marijuana and tobacco smoke. ‎Sci Rep 2020; 10(1): 1-12. https://doi.org/10.1038/s41598-020-63120-6
30. Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association Between Marijuana Use and Risk of Cancer: A Systematic Review and Meta-analysis. JAMA network open. 2019; 2(11): e1916318-e1916318. https://doi.org/10.1001/jamanetworkopen.2019.16318
31. Callaghan RC, Allebeck P, Akre O, McGlynn KA, Sidorchuk A. Cannabis use and incidence of testicular cancer: a 42-year follow-up of Swedish men between 1970 and 2011. Cancer Epidemiol Biomarkers Prev. 2017; 26(11): 1644-1652. https://doi.org/10.1158/1055-9965
32. Radhakrishnan R, Wilkinson ST, D’Souza DC. (2014). Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry. 2014; 5: 54-54. https://doi.org/10.3389/fpsyt.2014.00054
33. National Academies of Sciences Engineering and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research: National Academies Press. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK425753/.
34. Cohen K, Weizman A, Weinstein A. Positive and negative effects of cannabis and cannabinoids on health. ASCPT. 2019; 105(5): 1139-1147. https://doi.org/10.1002/cpt.1381
35. Byers C. (2017). Marijuana Smoking and the Risk of Developing COPD, Lung Cancer, And/or Chronic Respiratory Symptoms: A Systematic Review. The University of Arizona. Retrieved from https://repository.arizona.edu/bitstream/handle/10150/623758/ByersC%20Poster.pdf?sequence=1&isAllowed=y
36. Wang X, Derakhshandeh R, Liu J, Narayan S, Nabavizadeh P, Le S, et al. One minute of marijuana secondhand smoke exposure substantially impairs vascular endothelial function. JAHA. 2016; 5(8): e003858. https://doi.org/10.1161/JAHA.116.003858
37. Hartman RL, Huestis MA. (2013). Cannabis effects on driving skills. Clin Chem, 59(3): 478-492.
38. NIDA. (2020, April 6). Marijuana. Retrieved 2020, June 10 https://www.drugabuse.gov/publications/research-reports/marijuana/there-link-between-marijuana-use-psychiatric-disorders
39. Bloomfield MAP, Ashok AH, Volkow ND, Howes OD. The effects of Δ(9)-tetrahydrocannabinol on the dopamine system. Nature. 2016; 539(7629): 369-377. https://doi.org/10.1038/nature20153
40. Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, et al. Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. Cannabis Cannabinoid Res. 2018; 3(1): 94-107. https://doi.org/10.1089/can.2017.0047
41. Wolff V, Jouanjus E. Strokes are possible complications of cannabinoids use. Epilepsy & Behavior. 2017; 70: 355-363. https://doi.org/10.1016/j.yebeh.2017.01.031
42. Wolff V, Lauer V, Rouyer O, Sellal F, Meyer N, Raul JS, et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke. 2011; 42(6): 1778-1780. https://doi.org/10.1161/STROKEAHA.110.610915
43. Sharma P, Murthy P, Bharath MMS. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012; 7(4): 149-156.
44. Lee A, Ahmed C, Campbell A, Garber M, Palmisiano M, Neil D, et al. (2020). The Financial and Psychosocial Impact of Medicinal Cannabis.
45. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav. 2020; 102: 106635. https://doi.org/10.1016/j.yebeh.2019.106635
46. Perisetti A, Rimu AH, Khan SA, Bansal P, Goyal H. (2020). Role of cannabis in inflammatory bowel diseases. Ann Gastroenterol. 2020; 33(2): 134. https://doi.org/10.20524/aog.2020.0452
47. Kramer JL (2015) Medical marijuana for cancer. Ca-Cancer J Clin, 65(2), 109-122.
48. Desai AN, Patel P. Stopping the Spread of COVID-19. JAMA. 2020; 323(15): 1516-1516. https://doi.org/10.1001/jama.2020.4269
49. Abany Z. Coronavirus: The tide is coming for medicinal cannabis. 2020; Available from: https://www.dw.com/en/coronavirus-the-tide-is-coming-for-medicinal-cannabis/a-53371342.
50. Hill KP. Cannabinoids and the Coronavirus. Cannabis Cannabinoid Res. 2020; 5(2). https://doi.org/10.1089/can.2020.0035
51. Le J. (2019). Overview of Pharmacokinetics Retrieved from https://www.msdmanuals.com/professional/clinical-pharmacology/pharmacokinetics/overview-of-pharmacokinetics
52. Millar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018; 9: 1365. https://doi.org/10.3389/fphar.2018.01365
53. Klumpers LE, Thacker DL. A brief background on cannabis: From plant to medical indications. J AOAC Int. 2019; 102(2): 412-420. https://doi.org/10.5740/jaoacint.18-0208
54. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018; 84(11): 2477-2482. https://doi.org/10.1111/bcp.13710
55. Grotenhermen F. Clinical Pharmacokinetics of Cannabinoids. J Cannabis Ther. 2003; 3(1): 3-51. https://doi.org/10.1300/J175v03n01_02
56. Kis B, Ifrim FC, Buda V, Avram S, Pavel IZ, Antal D, et al. Cannabidiol—From plant to human body: A promising bioactive molecule with multi-target effects in cancer. Int J Mol Sci. 2019; 20(23): 5905. https://doi.org/10.3390/ijms20235905
57. Lucas CJ, Galettis P, Song S, Solowij N, Reuter SE, Schneider J, et al. Cannabinoid disposition after human intraperitoneal use: an insight into intraperitoneal pharmacokinetic properties in metastatic cancer. Clin Ther. 2018; 40(9): 1442-1447. https://doi.org/10.1016/j.clinthera.2017.12.008
58. Heuberger JA, Guan Z, Oyetayo O O, Klumpers L, Morrison PD, Beumer TL, et al. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short-and long-term pharmacokinetics. Clin Pharmacokinet. 2015; 54(2): 209-219. https://doi.org/10.1016/j.vascn.2017.02.003